As obe­si­ty mar­ket heats up, Am­gen leaves clues on Mar­i­Tide’s path for­ward

Am­gen of­fered a glance at plans for its obe­si­ty drug can­di­date Mar­i­Tide dur­ing its fourth-quar­ter earn­ings call, in­clud­ing the ex­ten­sion of an on­go­ing Phase II tri­al and a Phase III de­vel­op­ment path­way span­ning mul­ti­ple in­di­ca­tions. But the com­pa­ny kept the fin­er de­tails close to its chest.

Mar­i­Tide com­pris­es two GLP-1 ag­o­nist pep­tides linked with a GIP-in­hibitor an­ti­body back­bone. The drug can­di­date is dif­fer­en­ti­at­ed from No­vo Nordisk’s semaglu­tide, which acts on­ly on GLP-1, and Eli Lil­ly’s tirzepatide, which has a dual mech­a­nism but mim­ics GIP in­stead of in­hibit­ing it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER